Bepranemab

Phase 2Monoclonal antibody

UCB

Bepranemab is one of 71 biologic programs targeting Cognitive impairment. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Cognitive ImpairmentActive, not recruiting

Progressive Supranuclear PalsyActive, not recruiting

Cognitive ImpairmentPhase 2

Active, not recruiting

Progressive Supranuclear PalsyPhase 1

Active, not recruiting

Competition

Competitive Landscape

279 competitors in Cognitive Impairment

#DrugCompanyPhaseTrials

Actos

Takeda

Phase 3

3 2

Farxiga

AstraZeneca

Phase 3

1 3

Provigil

NNuvo Research GmbH

Phase 3

1 4

Xarelto

WWim Janssens

Phase 3

1 5

Aquasol E

NNational Eye Institute (NEI)

Phase 3

1 6

Viagra

VViatris Specialty LLC

Phase 3

1 7

Donepezil Hydrochloride

Eisai

Phase 3

3 8

Statins

Sanofi

Phase 3

1 9

Galantamine Hydrobromide

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

Phase 3

4 10

Karx-EC

Bristol-Myers Squibb

Phase 3

—

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Cognitive impairment1 trial

A Study to Test the Efficacy, Safety, and Tolerability of Bepranemab (UCB0107) in Patients With Mild Cognitive Impairment or Mild Alzheimer's Disease (AD)

Completed· UCB logo

UCB·Phase 2·NCT04867616·466 enrolled

Progressive Supranuclear Palsy1 trial

A Study to Test the Safety and Tolerability of UCB0107 in Study Participants With Progressive Supranuclear Palsy (PSP)

Completed· UCB logo

UCB·Phase 1·NCT04185415·25 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for Bepranemab. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Bepranemab compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Bepranemab. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — UCB company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Monoclonal antibody[2]
Highest Phase: Phase 2[1]
Company: UCB

Bepranemab

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Cognitive impairment1 trial

Progressive Supranuclear Palsy1 trial

References

Drug Info

Quick Facts

Related News